

HHS Public Access

Author manuscript *Hosp Pract (1995).* Author manuscript; available in PMC 2017 December 01.

Published in final edited form as:

Hosp Pract (1995). 2016 December ; 44(5): 260–265. doi:10.1080/21548331.2016.1250603.

Decreased rates of hypoglycemia following implementation of a comprehensive computerized insulin order set and titration algorithm in the inpatient setting

Naina Sinha Gregory, Jane Jeffrie Seley, Linda M. Gerber, Chin Tang, and David Brillon Joan and Sanford I Weill Medical College of Cornell University Ringgold standard institution – Endocrinology, 211 East 80th Street, New York, New York 10065, United States

Abstract

Objectives—More than one-third of hospitalized patients have hyperglycemia. Despite evidence that improving glycemic control leads to better outcomes, achieving recognized targets remains a challenge. The objective of this study was to evaluate the implementation of a computerized insulin order set and titration algorithm on rates of hypoglycemia and overall inpatient glycemic control.

Methods—A prospective observational study evaluating the impact of a glycemic order set and titration algorithm in an academic medical center in non-critical care medical and surgical inpatients. The initial intervention was hospital-wide implementation of a comprehensive insulin order set. The secondary intervention was initiation of an insulin titration algorithm in two pilot medicine inpatient units. Point of care testing blood glucose reports were analyzed. These reports included rates of hypoglycemia (BG < 70 mg/dL) and hyperglycemia (BG > 200 mg/dL in phase 1, BG > 180 mg/dL in phase 2).

Results—In the first phase of the study, implementation of the insulin order set was associated with decreased rates of hypoglycemia (1.92% vs 1.61%; p <0.001) and increased rates of hyperglycemia (24.02% vs 27.27%; p <0.001) from 2010 to 2011. In the second phase, addition of a titration algorithm was associated with decreased rates of hypoglycemia (2.57% vs 1.82%; p = 0.039) and increased rates of hyperglycemia (31.76% vs 41.33%; p<0.001) from 2012 to 2013.

Conclusions—A comprehensive computerized insulin order set and titration algorithm significantly decreased rates of hypoglycemia. This significant reduction in hypoglycemia was associated with increased rates of hyperglycemia. Hardwiring the algorithm into the electronic medical record may foster adoption.

Keywords

Hypoglycemia; Hyperglycemia; Inpatient Glycemic Control; Computerized Order Sets

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

1. Introduction

Achieving optimal glycemic control in the inpatient setting continues to be a tremendous challenge. It is estimated that 38% of hospitalized patients have hyperglycemia. Of this number, 26% have pre-existing diabetes with the remaining 12% having either newly diagnosed diabetes or stress hyperglycemia.¹ Although hyperglycemia is not the primary diagnosis in most cases, it has adverse effects on health outcomes.² There are numerous detrimental consequences to the immune, cardiovascular and central nervous systems leading to poor outcomes.³ Patients with hyperglycemia have an increased infection rate secondary to decreased leukocyte mobilization and phagocytic activity.⁴ Hyperglycemia is an important marker of poor clinical outcome and mortality not only in critically ill patients but also in those admitted to general medicine and surgery units.¹ Hypoglycemia is also associated with a higher risk of mortality in hospitalized patients. ⁵ In addition, poor glycemic control leads to higher admission rates as well as an increased need for support at home or in a facility following discharge. ⁶ The benefits of treating both hypo- and hyperglycemia result in decreased rates of morbidity and mortality as well as in cost savings such as decreased length of stay and rate of readmissions.⁷

Despite the evidence that improved inpatient glycemic control yields better outcomes, achieving recognized targets remain elusive. Insulin is the preferred agent in the inpatient setting due to its rapid onset of action and flexibility in adjusting doses as clinical status changes.³ Hospitalized patients have rapidly changing insulin requirements due to varying nutritional intake as well as fluctuations in the severity of their underlying illness.⁸ The 2013 American Society of Health-System Pharmacists (ASHP) Research and Education Foundation recommendations designated insulin as a high-alert medication across all inpatient settings.⁹ In annual surveys conducted by The Institute for Safe Medication Practices (ISMP), insulin continues to rank as one of the top high-risk medications in hospitals.¹⁰ The appropriate initiation and titration of insulin therapy is an ongoing challenge that contributes to clinical inertia, or the failure to advance therapy when needed.¹¹ Common root causes of clinical inertia when dosing insulin include lack of comfort level when prescribing, fear of inducing hypoglycemia, various training levels amongst prescribers as well as having to balance competing patient and institutional priorities.¹²

The primary aim of this study is to evaluate the safety and efficacy of a comprehensive insulin order set in the inpatient computer-based provider order-entry system (CPOE) to facilitate insulin dosing and its impact on glycemic control at NewYork-Presbyterian Hospital/Weill Cornell Medicine (NYPH/WC). Previous studies have suggested that structured insulin order sets promote insulin safety and efficacy.¹³ We posited that a standardized protocol with initial starting doses of both basal and bolus insulin would enhance the quality of care by improving overall glycemic control and reducing both insulin medication errors and rates of hypoglycemia.

2. Methods

The setting was an academic teaching hospital with an average of 60,000 inpatients per year and an overall inpatient mortality rate of 6.9%. The type 1 diabetes subgroup had an average A1c of 9.3% \pm 2.7% and the type 2 diabetes subgroup an A1c of 7.7% \pm 2.0%. Additional relevant demographics can be found in Table 1. In the first phase of this study, five comprehensive subcutaneous insulin order sets were launched in November 2010. These order sets were available hospital wide in all adult non-critical care areas, except for labor and delivery. The launch of the order sets was hospital-wide therefore all patients receiving subcutaneous insulin were using these order sets. There were no patients in the non-critical care medical and surgical floors that did not have their insulin ordered through these order sets. These order sets provided initial starting doses based on levels of insulin sensitivity for adult inpatients with hyperglycemia. The following five order sets were available: NPO, very low, low, medium and high dose. (See Figure 1- Screenshot of Aspart/Glargine Low Dose Order Set & Table 2 - Initial insulin doses for order sets). Clinicians received minimal training with a handout that included screenshots of the order sets and how to place orders. There was wide adoption of the order sets because of its simple and comprehensive nature, with pre-selected orders for diet, blood glucose (BG) monitoring, correction and mealtime insulin, treatment of hypoglycemia and diabetes education. Safety and efficacy of the insulin order sets was determined based on point of care BG testing (POCT) records stored in a database in the POCT laboratory. Reports were generated on a daily, monthly and annual basis and included rates of hypoglycemia (BG <70 mg/dL) and hyperglycemia (BG >200 mg/dL), as well as frequencies of BGs within the recommended range at that time of 70–200 mg/dl. These reports were based on aggregated data with no identifiable individual patient information included. BG POCT reports were analyzed on a monthly basis, comparing 2010 BG data to 2011 BG data.

Upon implementation of the order sets, the researchers discovered that there was reluctance on the part of prescribers to titrate the initial basal and the bolus insulin doses since the titrations were not auto-calculated. In response to this need, a second phase of the study was initiated and piloted in two general medicine units. It involved the development of a simple evidence-based titration algorithm based on BG target ranges to facilitate safe, timely and effective titration of both basal and bolus subcutaneous insulin. The algorithm was based on several inpatient studies that used dosing algorithms successfully.^{14,15,16} It is important to note that in 2012 we adopted the newly released Endocrine Society management of hyperglycemia guideline to maintain BG <180 mg/dL in the non-critical care setting.¹⁶ The new titration algorithm was designed to guide prescribers to adjust insulin based on patterns of glucose control over the previous 24-hour period. In May 2013, the inpatient diabetes nurse practitioner (JJS) piloted the algorithm with groups of medicine house staff responsible for ordering and titrating insulin. The education consisted of 15-minute group sessions offered twice a month on the medicine unit. To reinforce the teaching, a pocket card was distributed containing the key elements of the algorithm (Fig. 2 - Algorithm Version 1.0). In June 2013, house staff feedback indicated a lack of comfort calculating and entering the dose adjustments into the CPOE. This was due to an unforeseen hesitation when deciding which direction to round a fraction to a whole number and the cumbersome hand

entry process into the EMR. To address this concern, the intervention was modified by creating a new version of the algorithm that pre-calculated the doses for all the glucose ranges in the high dose order set by adding 10% when BG was between 180–250 mg/dL and 20% when BG was greater than 250 mg/dL. (See Fig 2- Algorithm Version 2.0). In September 2013, the inpatient diabetes nurse practitioner (JJS) re-educated the house staff in the new version of the algorithm and distributed a revised pocket card. After the education was completed, we analyzed three months of BG POCT data from the pilot medicine unit and compared it to the same three calendar months from the previous year.

Rates of hypoglycemia, BG in-target range, and hyperglycemia were calculated by year. The chi square test was used to compare the rates within each BG category by year. All statistical tests were two-sided and p < 0.05 was considered statistically significant. Analyses were performed in SAS version 9.1 (SAS Institute, Inc., Cary, North Carolina).

The study was approved by the Weill Cornell Medicine Institutional Review Board.

3. Results

In the first phase of the study, implementation of the insulin order sets was associated with a significant decrease in the rates of hypoglycemia from 2010 to 2011 (1.92% and 1.61%, respectively; p <0.001). At the same time, BG levels in target range decreased (74.06% vs 71.12%, respectively; p<0.001) and rates of hyperglycemia increased (24.02% vs 27.27%, respectively; p<0.001). In the second phase, with the addition of a titration algorithm to address hyperglycemia, rates of glycemia were re-evaluated. There was a significant decrease in hypoglycemia from 2012 to 2013 (2.57% vs 1.82% respectively; p = 0.039). In addition, there was a significant decrease in blood glucose levels in the target range from 2012 to 2013 (65.67% vs 56.85%; p<0.0001). Rates of hyperglycemia increased (31.76% vs 41.33%; p<0.001). (See Fig. 3)

4. Discussion

Our study showed that a comprehensive computerized insulin order set and titration algorithm was safe and resulted in decreased hypoglycemia with the unforeseen consequence of increased hyperglycemia. In response to the increase in hyperglycemia, the second phase of our study introduced an insulin titration algorithm to help with prescriber intensification of insulin doses based on glucose patterns. This titration algorithm did not appear to work optimally for the following reasons: Despite the distribution of a pocket card of the algorithm as an additional resource at the time of the educational intervention, adoption was slow. Careful examination of algorithm usage revealed resident reluctance to manually calculate doses and hand enter them into the computerized provider order entry (CPOE). To address this significant barrier, a new pocket card was created that precalculated the doses by adding 10% or 20% depending on the BG range. Although this strategy was intended to improve clinical practice behavior, the rate of adoption remained disappointing. In subsequent discussions with medical residents asked to use the algorithm, many complained about hand entering the new doses and requested that auto-calculation be

incorporated into the CPOE. One important future direction would include hardwiring the algorithm into our EMR with assistance from our information technology colleagues.

A strength of our study was the large BG POCT dataset captured from an 800 bed academic medical center. Another strength was the widespread adoption of the order set since it replaced the previous cumbersome method of separately entering insulin and other related orders such as BG monitoring and hypoglycemia treatment. The primary limitation of the study is that the effect of the intervention was restricted to changes in glycemic rates instead of patient outcomes. The clinical significance of the decrease in rates of hypoglycemia was not evaluated. The low p-values due to large numbers may contribute to the statistical significance observed in the rates of hypoglycemia. However, the rates of hypoglycemia are, fortunately, very uncommon in this hospital's setting so that a small difference in rates may be of clinical importance. Another limitation of working with a large BG POCT dataset is that specific information regarding the type of diabetes (ie. type 1, type 2 or new hyperglycemia) or degree of control (A1c) was not available. It was also not possible to perform an assessment of comorbidities using an Elixhauser or Charlson comorbidity score. Another limitation was that the implementation of the insulin titration algorithm was piloted on two general medicine units each with an average census of 35 patients and may not be generalizable to other inpatient units. The rates of compliance and adherence to the titration algorithm were not reported other than what was gathered through feedback at the time of the teaching sessions. This limits the conclusions that can be drawn about the efficacy of the algorithm.

Our study reinforces the ongoing difficulty in achieving recommended glycemic targets in the inpatient setting. Rogers's Diffusion of Innovations, a theoretical framework that helps address barriers to following clinical practice recommendations and offers possible solutions, can guide the development and testing of a comprehensive electronic insulin order set for prescribers in the inpatient setting when glycemic targets are not reached.¹⁷ A "Call to Action" consensus conference hosted by the American Association of Clinical Endocrinologists and the American Diabetes Association identified institutional insulin management protocols and standardized insulin order sets as essential interventions to address key barriers to inpatient glycemic control.¹⁸ An ASHP expert consensus panel concurred with these recommendations as well as the need to eliminate *sliding scale* insulin dosing and substitute it with protocol-driven evidence based insulin order sets.⁹ Since that time, many hospitals have built comprehensive insulin order sets with dosing recommendations to promote both safety and efficacy. Standardization of order sets along with staff education in glycemic control strategies are two ways that have been shown to mitigate common errors associated with insulin use.¹⁹

The fear that insulin use leads to an increased risk of hypoglycemia remains a strong contributor to clinical inertia. Interventions that increase prescriber comfort and knowledge when initiating and intensifying insulin therapy are important steps toward improving glycemic management in the hospital setting. A number of innovative strategies have been utilized to reduce clinical inertia and facilitate timely initiation and intensification of insulin therapy. These include the use of computer-based algorithms and information systems for decision support, automatic reminders of when to order tests and single "click" electronic

ordering. ²⁰ Donihi et al, found that insulin usage in the inpatient setting was associated with a number of medication errors along with adverse events such as hypoglycemia and hyperglycemia. The researchers instituted a standardized insulin order set along with preprinted prescriber orders forms. One year after protocol implementation, prescribing errors were significantly reduced from 10.3 per 100 patient days to 1.2 per 100 patient days (p=0.03). Additionally, hyperglycemia episodes 1 year after implementation decreased from 55.9 to 16.3 per 100 patient days. There was no associated increase in hypoglycemia.²¹

5. Conclusion

The implementation of a comprehensive glycemic management order set is an important tool to improve patient safety and quality. Prior studies provided evidence that the implementation of standardized insulin protocols for the management of inpatient hyperglycemia can lead to decreased episodes of hyperglycemia as well as decreased prescribing errors. It is important to assess the effects of implementation of insulin order sets on outcomes. Our study showed significant decreases in rates of hypoglycemia but rates of hyperglycemia increased secondary to lack of appropriate intensification of insulin treatment. An important next step will be to explore hardwiring the algorithm into our EMR to facilitate adoption by enhancing ease of use and availability of decision support.

Acknowledgments

Funding

Research reported in this publication was supported by the National Center for Advancing Translational Science of the National Institute of Health under Award Number UL1TR000457.

References

- Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of inhospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002; 87:978–982. [PubMed: 11889147]
- 2. Qureshi A, Deakins DA, Reynolds LR. Obstacles to optimal management of inpatient hyperglycemia in noncritically ill patients. Hosp Pract. 2012 Apr 1; 40(2):36–43.
- Mendez CE, Umpierrez GE. Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients. Diabetes Spectrum. 2014 Aug 1; 27(3):180–8. [PubMed: 26246777]
- 4. Butler S, Btaiche I, Alaniz C. Relationship between hyperglycemia and infection in critally ill patients. Pharmacotherapy. 2005 Aug; 25(7):963–76. [PubMed: 16006275]
- Kalfon P, Giraudeau B, Ichai, et al. Tight computerized versus conventional glucose control in the ICU: a randomized controlled trial. Intensive Care Med. 2014 Feb; 40(2):171–81. [PubMed: 24420499]
- 6. Society of Hospital Medicine Glycemic Control Task Force. [Accessed 05/4/2016] The Glycemic Control Implementation Guide: Improving Glycemic Control, Preventing Hypoglycemia, and Optimizing Care of the Inpatient with Hyperglycemia and Diabetes. Glycemic Control Quality Improvement Implementation Tool Kit. 2016. Available at http://www.hospitalmedicine.org
- 7. Hermayer KL, Cawley P, Arnold P, et al. Impact of improvement efforts on glycemic control and hypoglycemia at a university medical center. Journal of Hosp Medicine. 2009 Jul 1; 4(6):331–9.
- Ryan DB, Swift CS. The mealtime challenge: nutrition and glycemic control in the hospital. Diabetes Spectrum. 2014 Aug 1; 27(3):163–8. [PubMed: 26246774]

- 9. Cobaugh DJ, Maynard G, Cooper L, et al. Enhancing insulin-use safety in hospitals: Practical recommendations from an ASHP Foundation Expert Consensus Panel. Am J Health-Syst Pharm. 2013; 70:1404–13. [PubMed: 23903479]
- Institute for Safe Medication Practices. [Accessed April 6, 2016] ISMP List of High-Alert Medications in Acute Care Setting. 2016. Available at https://www.ismp.org/tools/ institutionalhighAlert.asp
- Wexler DJ, Meigs JB, Cagliero E, Nathan DM, Grant RW. Prevalence of hyper- and hypoglycemia among inpatients with diabetes: a national survey of 44 U.S. hospitals. 2007. Diabetes Care. 30:367–389. [PubMed: 17259511]
- 12. Mackey P, Boyle M, Walo P, Castro J, Cheng MR, Cook C. Care directed by a specialty-trained nurse practitioner or physician assistant can overcome clinical inertia in management of inpatient diabetes. Endocrine Practice. 2013 Sep 6.
- Maynard G, Lee J, Phillips GW, Fink E, Renvall M. Improved inpatient use of basal insulin, reduced hypoglycemia, and improved glycemic control: Effect of structured subcutaneous Insulin orders and insulin management algorithm. J Hosp Med. 2009; 4:3–15. [PubMed: 19140173]
- McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. Endocrinol Metab Clin North Am. 2012; 41:175–20. [PubMed: 22575413]
- Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007; 30:2181–2186. [PubMed: 17513708]
- Umpierrez GE, Hellman R, Korytkowski, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012; 97:16–38. [PubMed: 22223765]
- 17. Rogers EM. A prospective and retrospective look at the diffusion model. Journal of Health Communication. 2004; 9(S1):13–19. [PubMed: 14960401]
- Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009; 32(6):1119–1131. [PubMed: 19429873]
- Maynard G, Wesorick DH, O'Malley C, Inzucchi SE. Subcutaneous insulin order sets and protocols: effective design and implementation strategies. J Hosp Med. 2008; 3(5 Suppl):29–41. [PubMed: 18951386]
- 20. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers. Diabetes Care. 2005; 28:337–342. [PubMed: 15677789]
- Donihi AC, DiNardo MM, DeVita MA, Korytkowski MT. Use of a standardized protocol to decrease medication errors and adverse events related to sliding scale insulin. Qual Saf Health Care. 2006; 15(2):89–91. [PubMed: 16585106]

	_			_			
Diagnosis Drider	lin	aanosis		_	_	Comment	
= Diagnosis - 3 item(s)	101	ayross				(Contrient	
Diagnosis	T,	pe 1 Diabetes				Must Order Basal Insulin	
Diagnosis		pe 2 Diabetes					
Diagnosis	H3	perglycemia: No prior diagnosi:	s of Diabetes				
Nursing							
 Nursing - 3 item(s) 							
Fingerstick, Glucose	Routine	ac and bedtime	25-May-2010			Must be done within 1 hour	
Fingerstick, Glucose	Routine	q6h-(0,6,12,18)	T COLO			Tube Feedings or NPO Cor	
Notify MD/NP/PA	Routine	<continuous></continuous>	25-May-2010			For BG<70 or <100 with s	mptoms as indicated in the hypoglycemia protocol
Laboratory							
Order	Colle	ction Priority Colle	ction Date Proc	essing Priority		Comment	
Laboratory - 1 item(s)		Iraw - order before. T	Rou			Order X error	re available within the past 60 days.
Lu (as) Hemoglobin ATC	AM L	naw - order before 1	Hou	110		Urder if no results a	e available within the past 60 days.
Nutrition							
Order	Di	et Modifier Diet Modifier	(2) Diet Modifier (3) C	interia	Food Preference	Comment	and the second
- Nutrition - 3 item(s)					1		
Diabetes/Consistent Carb Diet Adul					No food.	55%, CH0, 25% fat and 20	
Diabetes/Consistent Carb Diet A					No food.	55%, CH0, 25% fat and 20 55%, CH0, 25% fat and 20	
Lim Diabeles/Consistent Carb Diet Adu	CO Calo.				Into tood.	100%, UNU, 20% fat and 20	> FIO ELS REGULTION.
Prandial Scale			10000	1	100000		
Order	Insulin: BG D	lose Unteria	Route	Frequency	Start Date	Start Time (Comment
Prandial Scale - 1 item(s) Insulin Aspart Prandial Scale Pre	O LINUT & D	e-Meal BG: Hypoglycemia Tx B	0. 0. 00 0.000	ac and bedlin		1	
Um insuin Aspalt Mandial Scale Me	U UNIT I PI				18		
Basal Insulin		0 UNIT if Pre-Meal BG	: Hypoglycemia Tx BG 0 : 70 - 100	- 03			
	Dose L	2 UNIT if Pre-Meal BG		18	tast Date	Start Time Comments	
- Basal Insulin - 1 item(s)	IL IL	3 UNIT if Pre-Meal BG		10	In the second se	Teambara	
Insulin Glargine Inj (Lantus)	U	NI 4 UNIT if Pre-Meal BG		T		Routine Weight-ca	culated, CONFIRM wt in kg, adjust dose as needed.
		5 UNIT if Pre-Meal BG					
Hypoglycemia Management		6 UNIT if Pre-Meal BG					
Typogycemia Management Order	Dose U	7 UNIT if Pre-Meal BG		leason	Start D	Date Start Time	Comment
= Hypoglycemia Management - 3 item(s)	100000 1101		:>400 Hypoglycemia Tx BG 0 -		Total to	Jorgen Lange	Decemente
Glucagon Inj	1 M	0 UNIT if Bedtime BG: 0 UNIT if Bedtime BG:		vcemia	25-Ma	w-2010 Routine	Give if NPO w/o IV access & BG<70 w/o symptoms
Dextrose 50% Inj	25 G	2 UNIT if Bedtime BG:		vcemia		y-2010 Routine	Give if NPO & BG<70 w/o symptoms OR <100.
Glucose Gel Oral	15 G	3 UNIT if Bedtime BG:		ycemia		y-2010 Routine	Give if PO diet, able to swallow & BG<70 or <100
4		4 UNIT if Bedtime BG:					
Teaching/Counseling							
		Frequency	Start Date S	tart Time	Instruction	Comment	
Order							
Urder - Nursing - 4 item(s)	1	1	Trans. The second secon		1 march		
	Routine	qshift qshift	25-May-2010 25-May-2010		PRN PRN	Insulin Self-Administration Blood Glucose Monitoring	

Figure 1. Screenshot of Aspart/Glargine Low Dose Order Set

Version 1.0 How to	Adjust Insulin	Vers	ion 2.0 ł	low to Adjus	t Insulin
	NALCODITURA	Increasing	Insulin Doses	When High Dose Orde	r Set Is Not E nough
INSULIN TITRATIO	N ALGORITHIVI	Prandial	High Dose	High Dose +10 %	High +20%
WHICH INSULIN NEED	S ADJUSTMENT:	Aspart 70-100	Aspart Doses	For BGs 180-250 mg/d1	For BGs>250mg/dl
		101-150	6	7	8
If AM fasting BG is too high	Adjust Glargine	151-200	8	9	10
or low:	, .	201-250	10	11	12
		251-300	12	13	14
If pre-lunch, pre-dinner or	Adjust Aspart	301-350	14	15	17
bedtime		350-400	16	18	19
is too high or low:		>400	18	20	22
		Bedtime	Bedtime	Bedtime	Bedtime
HOW TO AD	<u>JUSI:</u>	70-199	0	0	0
If BG is less than 50:	Deduct 50%	200-250	0	0	0
If BG is 50-69	Deduct 10%	251-300	0	2	3
		301-350	4	5	6
If BG is 180-250	Add 10%	351-400	6	7	8
If BG greater than 250:	Add 20%	>400	8	9	10

Figure 2. Algorithm Versions 1.0 and 2.0




Figure 3.




Table 1

Demographics of the Inpatient Population in 2013

iender 29,526 (c) Female 31,672 (c) Unknown 91 (0) oge (years) 18 18 8,841 (1) 19–24 1,398 (c) 25–34 4,068 (c) 35–44 6,842 (1) 45–54 5,172 (c) 55–64 6,291 (1) 65–74 8,248 (1) 75–84 8,129 (1) 85 12,300 (c) tace 21,349 (c) Mhite 21,349 (c) African-American 5,072 (c) Asian 2,796 (c) American Indian or Alaska Native 132 (0) Native Hawaiian or Pacific Islander 60 (0) Unknown 31,777 (c) nsurance 2,988 (c) Medicaid 2,987 (c) Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3	
Female 31,672 (* Unknown 91 (0. sge (years) 1 18 8,841 (1 19–24 1,398 (* 25–34 4,068 (* 35–44 6,842 (1 45–54 5,172 (* 55–64 6,291 (1 65–74 8,248 (1 75–84 8,129 (1 85 12,300 (* Cace 2 White 21,349 (* African-American 5,072 (* Asian 2,796 (* American Indian or Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (* nsurance 2,988 (* Medicaid 2,988 (* Multi	
Unknown 91 (0. ige (years) 18 18 8,841 (1 19–24 1,398 (2 25–34 4,068 (0 35–44 6,842 (1 45–54 5,172 (2 55–64 6,291 (1 65–74 8,248 (1 75–84 8,129 (1 85 12,300 (2 kace 21,349 (2 Mhite 21,349 (2 African-American 5,072 (3 Asian 2,796 (4 American Indian or Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (2 nsurance 2,988 (4 Medicaid 2,987 (4 Medicaid 2,987 (4 Medicaid	48.2%)
ige (years) 18 8,841 (1 19–24 1,398 (2 25–34 4,068 (0 35–44 6,842 (1 45–54 5,172 (3 55–64 6,291 (1 65–74 8,248 (1 75–84 8,129 (1 85 12,300 (2 cace 21,349 (2 Mhite 21,349 (2 African-American 5,072 (3 Asian 2,796 (2 American Indian or Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (2 nsurance 2,988 (2 Medicaid 2,988 (2 Medicaid 2,988 (2 Uninsured 449 (0 uninsured 449 (0 Medicaid 9,759 (1 Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m ²) 18.5 9,759 (1 18.6–25 17,320 (2	51.7%)
18 8,841 (1 19–24 1,398 (2 25–34 4,068 (0 35–44 6,842 (1 45–54 5,172 (2 55–64 6,291 (1 65–74 8,248 (1 75–84 8,129 (1 85 12,300 (2 kace 21,349 (2 White 21,349 (2 African-American 5,072 (3 Asian 2,796 (2 Asian 2,796 (2 Meticaid nor Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (2 nsurance 2,988 (2 Medicaid 2,988 (2 Medicaid 2,988 (2 Uninsured 449 (0 ength of Stay (days) 17.97 ± Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6–25 17,320 (2	2%)
19-24 1,398 (2) 25-34 4,068 (0) 35-44 6,842 (1) 45-54 5,172 (2) 55-64 6,291 (1) 65-74 8,248 (1) 75-84 8,129 (1) 85 12,300 (2) tace 21,349 (2) Mhite 21,349 (2) African-American 5,072 (2) Asian 2,796 (2) American Indian or Alaska Native 132 (0) Native Hawaiian or Pacific Islander 60 (0) Unknown 31,777 (2) nsurance 2,988 (2) Medicaid 2,988 (2) Commercial 38,091 (0) Uninsured 449 (0) ength of Stay (days) 17.9 ± Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m ²) 18.5 9,759 (1) 18.6-25 17,320 (2)	
25-34 4,068 (c) 35-44 6,842 (1) 45-54 5,172 (c) 55-64 6,291 (1) 65-74 8,248 (1) 75-84 8,129 (1) 85 12,300 (c) tace 21,349 (c) Mhite 21,349 (c) African-American 5,072 (c) Asian 2,796 (c) Native Hawaiian or Pacific Islander 60 (0) Unknown 31,777 (c) nsurance 2,988 (c) Medicaid 2,988 (c) Medicaid 2,988 (c) Total Inpatient Population 9,2 ± Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m ²) 18.5 9,759 (1) 18.6-25 17,320 (c)	4.4%)
35-44 6,842 (1 45-54 5,172 (2) 55-64 6,291 (1) 65-74 8,248 (1) 75-84 8,129 (1) 85 12,300 (2) tace 21,349 (2) Mhite 21,349 (2) African-American 5,072 (2) Asian 2,796 (2) American Indian or Alaska Native 132 (0) Native Hawaiian or Pacific Islander 60 (0) Unknown 31,777 (2) nsurance 400 (2) Medicaid 2,988 (2) Commercial 38,091 (0) Uninsured 449 (0) .ength of Stay (days) 17.9 ± Type 1 Diabetes (n= 301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m ²) 18.5 9,759 (1) 18.6-25 17,320 (2)	2.2%)
45-54 5,172 (3 55-64 6,291 (1 65-74 8,248 (1 75-84 8,129 (1 85 12,300 (2 cace 21,349 (2 Mhite 21,349 (2 African-American 5,072 (3 Asian 2,796 (2 American Indian or Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (3 nsurance 2,988 (2 Medicaid 2,988 (2 Uninsured 449 (0 ength of Stay (days) 17.9 ± Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6-25 17,320 (2	6.6%)
55-64 6,291 (1 65-74 8,248 (1 75-84 8,129 (1 85 12,300 (2 Cace 21,349 (2 White 21,349 (2 African-American 5,072 (2 Asian 2,796 (2 American Indian or Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (2 nsurance 2,988 (2 Medicaid 2,988 (2 Medicare 19,754 (2 Commercial 38,091 (0 Uninsured 449 (0 ength of Stay (days) 7.9 ± Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6-25 17,320 (2	1.2%)
65–74 8,248 (1 75–84 8,129 (1 85 12,300 (2 Cace 21,349 (2 Mhite 21,349 (2 African-American 5,072 (3 Asian 2,796 (2 American Indian or Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (2 nsurance 2,988 (2 Medicaid 2,988 (2 Medicare 19,754 (2 Commercial 38,091 (0 Uninsured 449 (0 ength of Stay (days) 17.9 ± Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6–25 17,320 (2	8.4%)
75-84 8,129 (1 85 12,300 (2 Race 21,349 (2 Mhite 21,349 (2 African-American 5,072 (2 Asian 2,796 (2 American Indian or Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (2 nsurance 60 (0. Medicaid 2,988 (2 Medicare 19,754 (2 Commercial 38,091 (0 Uninsured 449 (0 ength of Stay (days) 702 ± Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6-25 17,320 (2	0.3%)
85 12,300 (2 Race 21,349 (2 African-American 5,072 (3 Asian 2,796 (2 American Indian or Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (3 nsurance 2,988 (2 Medicaid 2,988 (2 Medicare 19,754 (3 Commercial 38,091 (0 Uninsured 449 (0 ength of Stay (days) 779 ± Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6–25 17,320 (2	3.5%)
Race 21,349 (2) African-American 5,072 (2) Asian 2,796 (2) American Indian or Alaska Native 132 (0) Native Hawaiian or Pacific Islander 60 (0) Unknown 31,777 (2) Insurance 2,988 (2) Medicaid 2,988 (2) Medicaid 2,988 (2) Commercial 38,091 (0) Uninsured 449 (0) ength of Stay (days) 7 Total Inpatient Population 9,2 ± Type 1 Diabetes (n=301; 0,01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1) 18.6–25 17,320 (2)	3.3%)
White 21,349 (c) African-American 5,072 (c) Asian 2,796 (c) American Indian or Alaska Native 132 (0) Native Hawaiian or Pacific Islander 60 (0) Unknown 31,777 (c) nsurance 2,988 (c) Medicaid 2,988 (c) Medicare 19,754 (c) Commercial 38,091 (c) Uninsured 449 (0) .ength of Stay (days) 779 ± Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1) 18.6–25 17,320 (c) 17.320 (c)	20.1%)
African-American 5,072 (3 Asian 2,796 (c American Indian or Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (3 nsurance Medicaid 2,988 (c Medicaid 2,988 (c Ommercial 38,091 (c Uninsured 449 (0 cength of Stay (days) Total Inpatient Population 9.2 ± Type 1 Diabetes (n=301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6–25 17,320 (2	
Asian 2,796 (c American Indian or Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (c nsurance 2,988 (c Medicaid 2,988 (c Medicare 19,754 (c Commercial 38,091 (c Uninsured 449 (0 .ength of Stay (days) 701 (17.9 ± Type 1 Diabetes (n= 301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6-25 17,320 (2	34.8%)
American Indian or Alaska Native 132 (0 Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (: insurance	8.3%)
Native Hawaiian or Pacific Islander 60 (0. Unknown 31,777 (c. insurance	4.6%)
Unknown 31,777 (: insurance Medicaid 2,988 (: Medicaid 2,988 (: (: Medicare 19,754 (: (: Commercial 38,091 (: (: Uninsured 449 (0 (: ength of Stay (days) Total Inpatient Population 9.2 ± Type 1 Diabetes (n= 301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6–25 17,320 (:	.2%)
Medicaid 2,988 (c Medicaid 2,988 (c Medicare 19,754 (c Commercial 38,091 (c Uninsured 449 (0 eength of Stay (days) 10 Total Inpatient Population 9.2 ± Type 1 Diabetes (n= 301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± EMI (kg/m²) 18.5 9,759 (1 18.6-25 17,320 (c	1%)
Medicaid 2,988 (c Medicare 19,754 (c Commercial 38,091 (c Uninsured 449 (0 eength of Stay (days) 7 Total Inpatient Population 9.2 ± Type 1 Diabetes (n= 301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6–25 17,320 (c	51.8%)
Medicare 19,754 (3 Commercial 38,091 (0 Uninsured 449 (0 ength of Stay (days) Total Inpatient Population 9.2 ± Type 1 Diabetes (n= 301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± EMI (kg/m ²) 18.5 9,759 (1 18.6-25 17,320 (2	
Commercial 38,091 (i Uninsured 449 (0 .ength of Stay (days)	4.9%)
Uninsured 449 (0 ength of Stay (days) 10 Total Inpatient Population 9.2 ± Type 1 Diabetes (n= 301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± EMI (kg/m²) 18.5 9,759 (1 18.6-25 17,320 (2	32.2%)
Arrow Constraint 9.2 ± Total Inpatient Population 9.2 ± Type 1 Diabetes (n= 301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± BMI (kg/m²) 18.5 9,759 (1 18.6-25 17,320 (2	62.1%)
Total Inpatient Population 9.2 ± Type 1 Diabetes (n= 301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6-25 17,320 (2	.7%)
Type 1 Diabetes (n= 301; 0.01%) 17.9 ± Type 2 Diabetes (n=3179; 5.19%) 10.8 ± BMI (kg/m²) 10.8 18.5 9,759 (1 18.6-25 17,320 (2	
Type 2 Diabetes (n=3179; 5.19%) 10.8 ± SMI (kg/m²) 18.5 9,759 (1 18.6–25 17,320 (2	18.5
BMI (kg/m²) 18.5 9,759 (1 18.6-25 17,320 (2	43.3
18.5 9,759 (1 18.6-25 17,320 (2	15.1
18.6–25 17,320 (2	
· · · · ·	5.9%)
	28.3%)
25.1–30 14,091 (2	23.0%)
30.1–40 8,967 (1	4.6%)

Number of patients admitted in 2013	n=61,289
Not Recorded	9.232 (15.1%)

Author Manuscript

Table 2

Author Manuscript

Author Manuscript

Initial insulin doses for order sets

		INSULIN ASPART GLARGINE	INSULIN ASPART GLARGINE SUBCUTANEOUS ORDER SETS		
	OdN	Poor PO Intake	Low	Medium	High
Indication	Use for short term NPO; If Type 1 Diabetes, must order basal insulin	Use for poor oral intake < 50% of tray	Use for elderly Type 1 Diabetes Lean body type Renal insufficiency; pancreatectomy	Use for average body size	Use for obesity; taking steroids
Glargine	None	0.1 unit/kg	0.15 unit/kg	0.2 unit/kg	0.3 unit/kg
BG frequency	Q 6hours (00,6,12,18)	AC (with meals and bedtime)	AC (with meals and bedtime)	AC (with meals and bedtime)	AC (with meals and bedtime)
BG			Initial Aspart Doses		
70-100	0 units	0 units	0 units	0 units	2units
101-150	0 units	0 units	0 units	4 units	6 units
151-200	1 units	2 units	3 units	5 units	8 units
201–250	2 units	3 units	4 units	6 units	10 units
251-300	3 units	4 units	5 units	7 units	12 units
301–350	4 units	5 units	6 units	8 units	14 units
351-400	5 units	6 units	7 units	9 units	16 units
>400	6 units	7 units	8 units	10 units	18 units
Bedtime BG			Initial Aspart Doses		
250–300		0 units	0 units	0 units	4 units
301–350		2 units	2 units	4 units	6 units
351-400		3 units	3 units	5 units	8 units
>400		4 units	4 units	6 units	10 units

Hosp Pract (1995). Author manuscript; available in PMC 2017 December 01.

Gregory et al.